Cyclacel Pharmaceuticals (CYCC) News & Sentiment

David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO

Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $7.35 per share a year ago.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul McBarron - EVP, Finance & COO Conference Call Participants Ahu Demir - Ladenburg Thalmann Grace Kim Good afternoon, everyone. And thank you for joining today's conference call to discuss Cyclacel's financial results and business highlights for the second quarter ended June 30, 2024.

Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $6.60 per share a year ago.

Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific  mechanism of action -

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) held its Q1 2024 Earnings Call on May 14, 2024 at 4:30 PM ET. Present on the call were Grace Kim - Investor Relations, Spiro Rombotis - President and CEO, Brian Schwartz - Chief Medical Officer, and Paul McBarron - Executive Vice President of Finance & COO. The conference call began with a welcome from the operator and all participants were in a listen-only mode.

Cyclacel Pharmaceuticals' stock is surging today following the company's decision to withdraw a public offering that was initially filed in March, as reported in an SEC filing.